People with HER2-positive gastric cancer should not take proton pump inhibitors for heartburn while they are undergoing treatment, recent studies have found.
Tumor-associated macrophages represent an exciting new target in the development of treatments for gastric cancer.
ALX Oncology won fast-track designation from the FDA for its drug ALX148 in the second-line treatment of patients with HER2-positive gastric cancer.
A review of clinical trials reveals that acupuncture and acupressure help reduce pain and opioid usage in cancer patients.
Two patients with gastroesophageal cancer responded well to Gritstone Oncology’s immune-stimulating treatment in an early trial.